StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$12.85−0.07 (-0.54%)

Close on Nov 17, 2026Market cap $171.97MP/E –Yield –

Anika Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Anika Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $27.45M, up 10.6% year over year. For fiscal 2025 it was $25.77M, up 0.9% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $27.33M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$25.77M+0.9%
FY2024Dec 31, 2024$25.54M+17.4%
FY2023Dec 31, 2023$21.76M+18.8%
FY2022Dec 31, 2022$18.32M-33.0%
FY2021Dec 31, 2021$27.33M+16.6%
FY2020Dec 31, 2020$23.43M+40.6%
FY2019Dec 31, 2019$16.67M-8.4%
FY2018Dec 31, 2018$18.19M-3.2%
FY2017Dec 31, 2017$18.79M+75.1%
FY2016Dec 31, 2016$10.73M+19.4%
FY2015Dec 31, 2015$8.99M+10.4%
FY2014Dec 31, 2014$8.14M+15.4%
FY2013Dec 31, 2013$7.06M+31.0%
FY2012Dec 31, 2012$5.39M-12.7%
FY2011Dec 31, 2011$6.17M-10.3%
FY2010Dec 31, 2010$6.87M-16.0%
FY2009Dec 31, 2009$8.18M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.34M+16.3%
Q1 FY2026Mar 31, 2026$6.71M+10.8%
Q4 FY2025Dec 31, 2025$6.45M-0.8%
Q3 FY2025Sep 30, 2025$6.95M+16.8%
Q2 FY2025Jun 30, 2025$6.31M-5.5%
Q1 FY2025Mar 31, 2025$6.06M-5.5%
Q4 FY2024Dec 31, 2024$6.51M-14.2%
Q3 FY2024Sep 30, 2024$5.95M-23.7%
Q2 FY2024Jun 30, 2024$6.68M-25.0%
Q1 FY2024Mar 31, 2024$6.41M-23.7%
Q4 FY2023Dec 31, 2023$7.59M-2.1%
Q3 FY2023Sep 30, 2023$7.79M+6.7%
Q2 FY2023Jun 30, 2023$8.91M+27.8%
Q1 FY2023Mar 31, 2023$8.40M+36.4%
Q4 FY2022Dec 31, 2022$7.75M+29.2%
Q3 FY2022Sep 30, 2022$7.30M-4.8%
Q2 FY2022Jun 30, 2022$6.98M-4.4%
Q1 FY2022Mar 31, 2022$6.16M-3.2%
Q4 FY2021Dec 31, 2021$6.00M-21.4%
Q3 FY2021Sep 30, 2021$7.67M+47.1%
Q2 FY2021Jun 30, 2021$7.29M+60.9%
Q1 FY2021Mar 31, 2021$6.36M+5.1%
Q4 FY2020Dec 31, 2020$7.63M+86.9%
Q3 FY2020Sep 30, 2020$5.22M+25.5%
Q2 FY2020Jun 30, 2020$4.53M+8.8%
Q1 FY2020Mar 31, 2020$6.05M+42.1%
Q4 FY2019Dec 31, 2019$4.08M+0.5%
Q3 FY2019Sep 30, 2019$4.16M-1.7%
Q2 FY2019Jun 30, 2019$4.17M-12.0%
Q1 FY2019Mar 31, 2019$4.26M-17.5%
Q4 FY2018Dec 31, 2018$4.06M-4.7%
Q3 FY2018Sep 30, 2018$4.23M-27.6%
Q2 FY2018Jun 30, 2018$4.73M+6.4%
Q1 FY2018Mar 31, 2018$5.16M+22.0%
Q4 FY2017Dec 31, 2017$4.27M+44.2%
Q3 FY2017Sep 30, 2017$5.84M+107.0%
Q2 FY2017Jun 30, 2017$4.45M–
Q1 FY2017Mar 31, 2017$4.23M–
Q4 FY2016Dec 31, 2016$2.96M–
Q3 FY2016Sep 30, 2016$2.82M–

More Anika Therapeutics figures

See a number that looks wrong?